START LOW I STAY LOW
when choosing a first-line treatment1,2

Achieve powerful IOP reduction with VYZULTA in your patients receiving their first IOP-lowering therapy1,2

In real-world practice, VYZULTA demonstrated IOP reduction in patients receiving first-line therapy2

High Baseline IOP (>21 mmHg; N=30)

comparative line graphs of high (41%) and low (22%) baseline IOP

Low Baseline IOP (≤21 mmHg; N=35)

comparative line graphs of high (41%) and low (22%) baseline IOP

More than half of patients treated first with VYZULTA had ≥30% IOP reduction from baseline at each follow-up visit2

Study Design

GET LOW I STAY LOW
when switching your patients from another therapy1,3

Achieve powerful IOP reduction with VYZULTA in your patients with inadequate response to other IOP-lowering therapies1,3

In real-world practice, VYZULTA demonstrated IOP reduction in patients switched from other IOP-lowering therapies.3

All Patients Switched to VYZULTA

comparative line graphs showing mean IOP reduction of all switch patients (25%) compared to patients switched from PGA monotherapy (26%)

Patients Switched to VYZULTA
Following PGA Monotherapy

Prior PGA monotherapy included bimatoprost (n=11),
latanoprost (n=10), travoprost (n=9), and tafluprost (n=2)

comparative line graphs showing mean IOP reduction of all switch patients (25%) compared to patients switched from PGA monotherapy (26%)

3 in 5 patients with mild to moderate glaucoma who switched to VYZULTA showed IOP reduction of ≥5 mmHg from baseline at each follow-up visit3

Study Design

PGA=prostaglandin analog.

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here to see full Prescribing Information.

References: 1. VYZULTA. Prescribing Information. Bausch & Lomb Inc. 2. Okeke CO, et al. Ophthalmol Ther. 2020;9(4):1041-1053. 3. Okeke CO, et al. Clin Ophthalmol. 2024;18:409-422.

Expand

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent